Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-dose Rivaroxaban Monotherapy Versus Guideline Determined Medication Therapy After Left Atrial Appendage Occlusion: a Randomized, Open-label, Multicentre, Superiority Trial

NCT05960721 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05960721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05960721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-dose Rivaroxaban Monotherapy Versus Guideline Determined Medication Therapy After Left Atrial Appendage Occlusion: a Randomized, Open-label, Multicentre, Superiority Trial
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
July 6, 2023
Completion date
July 30, 2028
Enrollment
4,220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation